Andy Chen
Stock Analyst at Wolfe Research
(2.05)
# 2,789
Out of 4,827 analysts
34
Total ratings
41.67%
Success rate
-4.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $7.25 | +189.66% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $20.07 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $30.74 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $7.75 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $9.29 | +115.29% | 1 | Feb 4, 2025 | |
| VERA Vera Therapeutics | Initiates: Outperform | $49 | $22.02 | +122.52% | 1 | Feb 4, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $19 | $9.04 | +110.18% | 1 | Feb 4, 2025 | |
| IMVT Immunovant | Downgrades: Peer Perform | n/a | $13.85 | - | 2 | Jan 3, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $697 | $615.11 | +13.31% | 2 | Nov 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Underperform | n/a | $269.81 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $59.66 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $18.40 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $39.36 | - | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $28.55 | +127.67% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $42.04 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $295.46 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.02 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $0.81 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $31.88 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $33.16 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.07 | +53.57% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $450.03 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $67.87 | -38.12% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $0.79 | +7,494.94% | 1 | Aug 8, 2023 |
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $7.25
Upside: +189.66%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $20.07
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $30.74
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $7.75
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $9.29
Upside: +115.29%
Vera Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $22.02
Upside: +122.52%
Zenas BioPharma
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $9.04
Upside: +110.18%
Immunovant
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $13.85
Upside: -
argenx SE
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $615.11
Upside: +13.31%
Alnylam Pharmaceuticals
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $269.81
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $59.66
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $18.40
Upside: -
Aug 26, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $39.36
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $28.55
Upside: +127.67%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $42.04
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $295.46
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $12.02
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $0.81
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $31.88
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $33.16
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.07
Upside: +53.57%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $450.03
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $67.87
Upside: -38.12%
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $0.79
Upside: +7,494.94%